Hua Medicine (Shanghai) Ltd.
Status: Publicly traded
Direct answer
Hua Medicine (Shanghai) Ltd. is publicly traded on HKSE under the ticker 2552.HK.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various...
Can you invest in Hua Medicine (Shanghai) Ltd.?
Yes. Hua Medicine (Shanghai) Ltd. is publicly traded on HKSE under the ticker 2552.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Hua Medicine (Shanghai) Ltd.
Detailed equity research is provided by MarketSnap.